Crinetics Pharmaceuticals Inc (CRNX) FinancialsCRNXFinancialCrinetics Pharmaceuticals Inc

Evaluating the bottom line, Crinetics Pharmaceuticals, Inc. maintains a gross margin of 99.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -527.35%, while the net margin is -481.15%. These profitability ratios, combined with a Return on Equity (ROE) of -42.45%, provide a clear picture of how effectively CRNX converts its operational activities into shareholder value.

In the context of the broader market, CRNX competes directly with industry leaders such as PTGX and IBRX. With a market capitalization of $9.00B, it holds a significant position in the sector. When comparing efficiency, CRNX's gross margin of 99.39% stands against PTGX's 100.00% and IBRX's 99.42%. Such benchmarking helps identify whether Crinetics Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Crinetics has shown a gross margin of 99.39% in Q2 2026, reflecting strong profitability on sales, but it has also reported substantial net losses, with a net income of -120,855,000 USD in Q2 2026.